ACE2 and COVID-19: Dysregulated RAAS due to ACE‐2 inhibition in COVID‐19 can also activate mitogen‐activated protein kinases (ERK, p38, and JNK), that are early activated in the innate immune response, and thus increase the risk of thrombosis.3